GleamWall
中文EN

CLNN Clene Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1822791 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-47.7%
TTM net income YoY20.4%
TTM EPS YoY—
Revenue 3-yr CAGR-22.1%
Net income 3-yr CAGR—

Margins

Gross margin79.5%
Operating margin-9,676.3%
Net margin-11,520.5%
FCF margin-6,240.1%
EBITDA margin-9,195.3%

Returns

ROE-1,738.4%
ROA-98.9%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets132.4%
Debt / equity—
Current ratio1.57x
Interest coverage-8.14x

Cash quality & payout

Operating cash flow / net income0.54x
Accruals ratio-45.4%
Payout ratio—
Capex / revenue4.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$56,000$90,000$15,000$77,000$15,000$27,000$81,000$91,000
Cost of revenue$16,000$36,000$0$23,000$0$0$20,000$18,000
Gross profit$40,000$54,000$15,000$54,000$15,000$27,000$61,000$73,000
R&D expense$4.45M$3.47M$329,000$5.50M$3.51M$3.51M$1.48M$5.57M
SG&A expense$1.94M$1.93M$1.75M$2.05M$2.15M$2.38M$2.66M$3.16M
Operating income-$6.35M-$5.35M-$2.06M-$7.50M-$5.65M-$5.86M-$4.08M-$8.65M
Interest expense$665,000$695,000$791,000$746,000$649,000$679,000$608,000$516,000
Pretax income$3.92M-$13.42M-$8.09M-$9.23M-$8.78M-$7.42M-$751,000-$13.55M
Income tax$0$0$0$0$0$0$0$0
Net income$3.92M-$13.42M-$8.09M-$9.23M-$8.78M-$7.42M-$751,000-$13.55M
EBITDA-$6.00M-$4.99M-$1.71M-$7.13M-$5.28M-$5.50M-$3.67M-$8.25M
EPS (basic)0.30-1.08-0.69—-0.85-0.78-0.09—
EPS (diluted)0.05———-0.85———
Weighted avg. shares (diluted)14.67M———10.28M———
Balance sheet
Cash & equivalents$9.89M$9.67M$5.94M$5.19M$7.98M$7.34M$9.89M$12.15M
Short-term investments———————$0
Receivables$43,000$43,000—$0$0$0$0$64,000
Inventory$41,000$37,000$54,000$37,000$61,000$79,000$38,000$68,000
Current assets$14.49M$14.91M$13.02M$8.98M$12.67M$11.98M$14.67M$16.16M
PP&E, net$5.02M$5.32M$5.67M$6.02M$6.36M$6.71M$7.08M$7.48M
Total assets$22.16M$23.04M$21.66M$18.13M$22.31M$22.12M$25.31M$27.34M
Current liabilities$17.11M$4.85M$6.73M$10.78M$8.31M$7.57M$10.76M$10.29M
Long-term debt$17.51M$17.60M$17.70M$17.79M$17.88M$16.46M$16.63M—
Total debt$17.51M$17.60M$17.70M$17.79M$17.88M$16.46M$16.63M—
Total liabilities$36.97M$47.82M$40.47M$35.72M$34.67M$30.68M$30.29M$36.19M
Shareholders' equity-$14.81M-$24.78M-$18.81M-$17.59M-$12.36M-$8.55M-$4.97M-$8.86M
Net debt$7.62M$7.93M$11.76M$12.60M$9.89M$9.12M$6.74M—
Shares outstanding14.21M12.78M11.78M10.85M10.22M9.46M8.67M8.09M
Cash flow statement
Operating cash flow-$4.62M-$2.59M-$4.53M-$4.80M-$3.99M-$4.74M-$5.01M-$4.87M
Capital expenditure$51,000——$28,000$11,000$0$0$1,000
Free cash flow-$4.67M——-$4.83M-$4.00M-$4.74M-$5.01M-$4.87M
Investing cash flow-$51,000-$1,000$0-$28,000-$11,000$0$0-$2,000
Financing cash flow$4.87M$6.33M$5.23M$2.07M$4.64M$2.13M$2.67M$2.53M
Depreciation & amortization$349,000$353,000$355,000$360,000$365,000$366,000$404,000$405,000
Stock-based compensation$1.08M$1.04M$1.31M$1.36M$1.70M$1.37M$1.95M$1.80M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.